Last reviewed · How we verify

SonoVue®

GE Healthcare · Phase 3 active Small molecule

SonoVue is a microbubble ultrasound contrast agent that enhances ultrasound imaging.

SonoVue is a microbubble ultrasound contrast agent that enhances ultrasound imaging. Used for Enhanced ultrasound imaging of the liver, spleen, and other organs.

At a glance

Generic nameSonoVue®
Also known assulfur hexafluoride microbubbles, SonoVue sulphur hexafluoride microbubbles 8 microlitres/ml, Powder and solvent for dispersion for injection., MARKETING AUTHORISATION NUMBER(S): EU/1/01/177/002, sulfur hexafluoride lipid-type A microspheres
SponsorGE Healthcare
Drug classUltrasound contrast agent
ModalitySmall molecule
Therapeutic areaImaging
PhasePhase 3

Mechanism of action

It works by producing a large number of microbubbles that reflect sound waves, allowing for improved visualization of blood flow and tissue perfusion.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: